ScholarlyCommons
metadata only
Genetic Evaluation of THRB as a Drug-Target Proxy and Modifier of GLP-1–Based Treatment Response
Background: Resmetirom, a selective thyroid hormone receptor beta (THRB) agonist, was approved for metabolic dysfunction-associated steatohepatitis (MASH) in 2024, yet real-world effectiveness data remain limited because of its high cost. Here, we used complementary human genetics and a real-world p
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Non-Alcoholic Fatty Liver Disease in a Saudi Cohort With Type 2 Diabetes Mellitus#854398
- Updated global consensus recommendations for risk stratification, treatment initiation, and response monitoring in metabolic dysfunction-associated steatotic liver disease#276158
- Accumulation of Lipid Droplets as an Underlying Cause of the Progression of Fatty Liver Disease to Liver Cancer#993261
- Development of a Genetic Score as a Response Modifier for Changes in Weight, Body Composition, and Biochemical Parameters in Obese Adults Undergoing a Low-Energy High-Protein Diet Intervention#825440
- NIH-FDA Nutrition Regulatory Science Workshop: advancing research and policy.#222954
Record · ID 1168940
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive